Pradaxa News - Bleeding Issues
Pradaxa News
  • Bad News For Boehringer-Ingelheim

    German pharmaceutical giant Boehringer-Ingelheim got some very unwelcome news just before the new year. Unfortunately, it wasn't about lawsuits, fines and penalties. It was about the competition. As one of its final actions for 2012, the U.S. Food and Drug Administration approved the anti-coagulant drug apixaban – a product that Bristol-Myers Squibb and Pfizer sells under the brand name Eliquis.

    read more
  • It's Nothing New

    Some of the companies currently facing major litigation over defective and dangerous products include Fresenius, maker of Granuflo, the dialysis drug, Stryker, a manufactuer of hip implants, and Boehringer-Ingelheim, which produces the stroke medication Pradaxa.

    read more
  • Boehringer-Ingelheim is Still At It

    Recently, global pharmaceutical giant Boehringer-Ingelheim (BI) posted a press release (dated 10 December 2012) on numerous sites on the World Wide Web, proclaiming triumphantly that

    “Results from a new post-hoc analysis of the landmark RE-LY® trial show that in patients experiencing a major bleeding event, treatment with Pradaxa® (dabigatran etexilate) was associated with lower mortality and a shorter length of stay in intensive care compared to warfarin.”

    read more
  • Another Victory for Big Pharma

    Nearly three years since the contemptible and outrageous Citizens United v. FEC ruling by the U.S. Supreme Court – which gave corporations (both foreign and domestic) the right to give unlimited amounts of money to political candidates and campaigns (anonymously) under the guise of “free speech” - a federal court has handed down yet another questionable decision that could affect the rights of patients and the ability of government to hold pharmaceutical corporations accountable.

    It's already been called “Citizens United Redux.”

    read more
  • Pradaxa Use Continues To Increase

    There is no question that dabigatran – produced by German pharmaceutical giant Boehringer-Ingeheim (BI) and sold under the brand name Pradaxais dangerous and has resulted in fatal hemorrhaging in as many as 10% of patients for whom it has been prescribed. Most recently, a 92-year-old patient died prematurely after ingesting only a single dose.

    read more
  • Pradaxa Litigation - Off and Running

    On Wednesday, 3 October 2012, attorneys for the Pradaxa victims and German pharmaceutical company Boehringer-Ingelheim (BI) met before the the Honorable Judge David Herndon. This meeting was the culmination of months of negotiation between the two sides, and among other issues, established numerous deadlines for the completion of steps leading to five “bellwether trials.” These trials will set precedents for other Pradaxa cases going forward.

    read more

Pages